Search results
Results From The WOW.Com Content Network
Pfizer Inc. (PFE) reported second-quarter financial results this morning. The world's largest drugmaker's profit tumbled 19 percent, although it slightly exceeded analysts' estimates. Revenue was ...
Pfizer (NYSE: PFE) has hit a bit of a ... That might seem bad, but those deliveries offered thin profit margins, ... if you invested $1,000 when we doubled down in 2009, you’d have $361,466!*
As investors, we need to understand how our companies truly make their money. A neat trick developed for just that purpose -- the DuPont formula -- can help us do so. So in this series we let the ...
Pfizer (NYS: PFE) and Biocon are getting a divorce. The press release said the companies had "individual priorities for their respective biosimilars businesses" -- the drugmaker-partnership ...
Pfizer: Astra Zeneca: 99 127 AstraZeneca claimed the deal undervalued the company. [16] 5 1999 Pfizer: Warner–Lambert: 82.4 151 Pfizer made a hostile bid, just after the announcement of a $72 billion deal with Wyeth, the eventual purchase price would be in excess of $90 billion. [17] [18] [19] 6 1999 Wyeth: Warner–Lambert: 72 132
The 10-second takeaway For the quarter ended Dec. 31 (Q4), Pfizer beat expectations on revenues and beat expectations on earnings per share. Compared to the Pfizer Beats on Both Top and Bottom Lines
In 2009, the Government-funded National Prescribing Service launched the "Finding Evidence – Recognising Hype" program, aimed at educating GPs on methods for independent drug analysis. [ 113 ] Meta-analyses have shown that psychiatric studies sponsored by pharmaceutical companies are several times more likely to report positive results, and ...
The 10-second takeawayFor the quarter ended July 1 (Q2), Pfizer met expectations on revenues and beat expectations on earnings per share. Compared to the Pfizer Beats Analyst Estimates on EPS